• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Eyenovia Inc.

    3/31/25 4:01:18 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email
    NT 10-K 1 tm251091d2_nt10k.htm NT 10-K

      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

     

    (Check one):

    x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D

    ¨ Form N-CEN ¨ Form N-CSR

       
     

    For Period Ended: December 31, 2024

    ¨ Transition Report on Form 10-K

    ¨ Transition Report on Form 20-F

    ¨ Transition Report on Form 11-K

    ¨ Transition Report on Form 10-Q

    For the Transition Period Ended: ____________________

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Eyenovia, Inc.
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    23461 South Pointe Drive, Suite 390
    Address of Principal Executive Office (Street and Number)
     
    Laguna Hills, CA 92653
    City, State and Zip Code

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      x   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
        (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
        (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

     

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Eyenovia, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”) by the March 31, 2025, filing deadline applicable to non-accelerated filers due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date, which is April 15, 2025.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

     

      Michael Rowe   833   393-6684
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes x No ¨
       
     
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes x No ¨
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Registrant expects to record a significant, non-cash impairment charge for the year ended December 31, 2024, due to the uncertainty associated with the Registrant’s current exploration of its strategic alternatives. The dollar amount of the impairment charge remains subject to internal review.

     

     

    Eyenovia, Inc. 

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2025  By: /s/ Michael Rowe, Chief Executive Officer

      

     

    Get the next $EYEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

    Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it is rebranding and changing its corporate name to Hyperion DeFi, Inc. Concurrent with the name change, the Company's

    7/2/25 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement

    LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 per token. "We continue to see strong signals from the market and prospective partners affirming the importance of HYPE's role in next-generation financial infrastructure," said Hyunsu Jung, Chief Investment Officer of Eyenovia. "This latest token acq

    6/30/25 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Co-Branded Validator with Kinetiq

    LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem.  The validator marks a significant step in Eyenovia's onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier

    6/25/25 8:30:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Jung Hyunsu was granted 500,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:04:50 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacobson Rachel was granted 5,000 shares, increasing direct ownership by 384% to 6,301 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:04:18 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rowe Michael M was granted 6,600 shares, increasing direct ownership by 480% to 7,975 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:03:45 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    8/28/24 8:01:36 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    8/27/24 1:06:37 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    7/3/24 3:18:06 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Eyenovia Inc.

    PRE 14A - HYPERION DEFI, INC. (0001682639) (Filer)

    7/11/25 8:26:03 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Eyenovia Inc.

    SCHEDULE 13D/A - HYPERION DEFI, INC. (0001682639) (Subject)

    7/2/25 4:49:54 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    7/2/25 4:16:10 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eyenovia downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    11/18/24 7:44:30 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

    HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

    4/1/21 6:45:58 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Northland Capital initiated coverage on Eyenovia with a new price target

    Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

    3/1/21 9:11:48 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Leadership Updates

    Live Leadership Updates

    View All

    Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

    LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to

    6/18/25 8:32:42 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

    NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

    9/3/24 7:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

    NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs. Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Exec

    7/27/22 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Financials

    Live finance-specific insights

    View All

    Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and webcast today, November 12th, at 4:30 pm ET NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing adv

    11/12/24 4:05:00 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

    NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714. To access t

    11/7/24 7:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced development collaborations with Formosa, Senju and SGN to leverage the Optejet for the $5 billion global dry eye disease market Company to host conference call and webcast today, August 12th, a

    8/12/24 4:05:00 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

    SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

    11/14/24 5:08:44 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    7/18/24 7:46:49 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care